FDA formally certified, safety assurance under regulatory standards

📌 Tipoline was approved by the U.S. FDA in 2022 for the treatment of type 2 diabetes , and passed FDA review again in November 2023 for the management of obesity and overweight in adults.

Certification Status	Authorized Use	Core Standards
May 2022	Type 2 diabetes mellitus aids in lowering blood sugar	Randomized controlled clinical data, superior to existing GLP-1 drugs
November 2023	Obesity ( BMI ≥ 30 ) or overweight ( BMI ≥ 27 with chronic diseases)	Must have long-term weight loss data and no significant risks

📌FDA approval must meet the following core requirements:

1. ≥10% average weight loss (far exceeding traditional weight loss drugs such as Orlistat and Contrave )
2. The side effects are controllable and there is no risk of long-term disability
3. Suitable for at least 1 year of continuous use

✅ In clinical practice, tebuconazole not only meets the standard, but also far exceeds the standard: weight loss can reach 22.5% and is well tolerated.

 

2. Clinical research results are authentic and reliable: from the SURMOUNT series of trials

📌 SURMOUNT-1 ( 72 weeks, obese adults)

•       Average weight loss: 22.5%

•       Proportion of people with a weight loss of ≥20% : 57.4%

•       Surpassing Wegovy ( 16.9% ) and other GLP-1 products

📌 SURMOUNT-2 (for patients with type 2 diabetes)

•       Average weight loss: 15.7%

•       Blood sugar and insulin indicators improved significantly

📌 Visceral fat reduction : about 32% 📌 Average waist reduction : 19cm+

✅ All these studies were double-blind, placebo-controlled and met international authoritative medical standards.

 

3. Why is the mechanism of tepote stronger?

Element	Function	Clinical advantages
GLP-1 agonists	Suppress appetite and delay gastric emptying	Control your food intake and reduce calorie intake
GIP agonists	Improve fat metabolism and insulin sensitivity	Promote fat burning and avoid hypoglycemia

📌 Compared with traditional GLP-1 drugs (such as semaglutide), telportide has an additional pathway to " improve metabolic efficiency " , which is particularly suitable for obese people with metabolic disorders and severe insulin resistance.

 

4. What is the safety data? Can it be used long-term?

📌 Types of side effects (controllable):

•       Mainly gastrointestinal reactions (such as nausea, diarrhea, constipation), usually appear in the first 4-6 weeks, and gradually improve after adaptation

•       Non-addictive, does not affect cognition, and does not inhibit the central nervous system

📌 Adverse event rates lower than most weight loss drugs

•       No severe hypoglycemia (unless concomitant hypoglycemic medication is used)

•       No liver and kidney toxicity, no carcinogenic risk data

•       No long-term cognitive impairment or psychiatric side effects were documented

✅ Long-term studies ( ≥1 year) have shown that weight maintenance after discontinuation of tebuconazole is significantly better than that of traditional drugs, and no serious safety risks have been found.

 

5. Why is tepote the symbol of “ trustworthiness ” ?

✅ Backed by authoritative regulators ( FDA )

✅ Supported by open and transparent clinical data

✅ The mechanism is scientific and clear, and the risk control is reasonable

✅ Real use cases show stable and long-term effects

📌 Conclusion: It is not a " quick-acting drug " but a " mechanism drug " - it is one of the medical weight loss programs that is closest to " metabolic reconstruction " .

 

Welcome to scroll down to the bottom of the page to add customer service to get a new customer discount